Tieton Capital Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-118,456
| Closed | -$3.27M | – | 33 |
|
|
2021
Q4 | $3.27M | Sell |
118,456
-10,955
| -8% | -$317K | 1.83% | 26 |
|
|
2021
Q3 | $4.18M | Sell |
129,411
-3,760
| -3% | -$125K | 2.27% | 21 |
|
|
2021
Q2 | $4.07M | Sell |
133,171
-49,950
| -27% | -$1.44M | 2.17% | 22 |
|
|
2021
Q1 | $5.58M | Sell |
183,121
-4,515
| -2% | -$128K | 3.21% | 17 |
|
|
2020
Q4 | $3.71M | Sell |
187,636
-6,334
| -3% | -$102K | 2.72% | 21 |
|
|
2020
Q3 | $2.53M | Buy |
193,970
+27,529
| +17% | +$348K | 2.5% | 22 |
|
|
2020
Q2 | $1.89M | Buy |
166,441
+1,790
| +1% | +$25.4K | 2.36% | 21 |
|
|
2020
Q1 | $2.36M | Sell |
164,651
-16,389
| -9% | -$346K | 3.79% | 16 |
|
|
2019
Q4 | $4.93M | Buy |
181,040
+9,206
| +5% | +$253K | 3.94% | 10 |
|
|
2019
Q3 | $4.92M | Buy |
171,834
+11,400
| +7% | +$332K | 4.19% | 10 |
|
|
2019
Q2 | $4.46M | Buy |
160,434
+62,235
| +63% | +$1.76M | 3.9% | 12 |
|
|
2019
Q1 | $3.26M | Buy |
98,199
+86,229
| +720% | +$2.62M | 2.9% | 21 |
|
|
2018
Q4 | $348K | Sell |
11,970
-79,978
| -87% | -$2.88M | 0.39% | 30 |
|
|
2018
Q3 | $4.23M | Sell |
91,948
-30,450
| -25% | -$1.35M | 3.37% | 16 |
|
|
2018
Q2 | $4.57M | Sell |
122,398
-30
| -0% | -$1.01K | 3.54% | 14 |
|
|
2018
Q1 | $3.62M | Sell |
122,428
-1,910
| -2% | -$64.6K | 3.32% | 18 |
|
|
2017
Q4 | $4.27M | Sell |
124,338
-126,805
| -50% | -$4.28M | 3.67% | 15 |
|
|
2017
Q3 | $9.09M | Sell |
251,143
-15,350
| -6% | -$438K | 7.81% | 2 |
|
|
2017
Q2 | $6.89M | Sell |
266,493
-30,675
| -10% | -$651K | 6.36% | 3 |
|
|
2017
Q1 | $5.71M | Buy |
297,168
+104,073
| +54% | +$1.84M | 4.95% | 6 |
|
|
2016
Q4 | $3.22M | Sell |
193,095
-920
| -0.5% | -$16.6K | 2.51% | 21 |
|
|
2016
Q3 | $3.99M | Buy |
194,015
+92,225
| +91% | +$2.34M | 3.43% | 17 |
|
|
2016
Q2 | $3.12M | Sell |
101,790
-5,667
| -5% | -$197K | 3.03% | 16 |
|
|
2016
Q1 | $4.02M | Sell |
107,457
-11,833
| -10% | -$446K | 3.85% | 14 |
|
|
2015
Q4 | $5.15M | Sell |
119,290
-22,120
| -16% | -$934K | 4.04% | 12 |
|
|
2015
Q3 | $5.3M | Sell |
141,410
-2,249
| -2% | -$79.8K | 4.95% | 7 |
|
|
2015
Q2 | $4.88M | Sell |
143,659
-2,991
| -2% | -$102K | 3.81% | 11 |
|
|
2015
Q1 | $5.19M | Buy |
146,650
+2,740
| +2% | +$98.1K | 3.9% | 13 |
|
|
2014
Q4 | $4.9M | Sell |
143,910
-118,875
| -45% | -$4.22M | 4.04% | 14 |
|
|
2014
Q3 | $10.1M | Buy |
+262,785
| New | +$9.81M | 7.43% | 1 |
|
Other funds holding MYGN
CCM
Tieton Capital Management's MYGN Position: Q1 2022 in Review
Tieton Capital Management sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 118,456 shares — an estimated $3.27M sold.
Tieton Capital Management first reported a position in MYGN in Q3 2014 and held it in 30 quarters. The position peaked at $10.1M in Q3 2014. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.
- Tieton Capital Management reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
- Tieton Capital Management sold 118,456 Myriad Genetics shares in Q1 2022, an estimated $3.27M.
- Tieton Capital Management first reported a position in Myriad Genetics in Q3 2014 and held it in 30 quarters.
- Tieton Capital Management's Myriad Genetics position peaked at $10.1M in Q3 2014.
- 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.
Based on Tieton Capital Management's 13F filing for Q1 2022, filed 10 May 2022.